In a 2014 study, tesamorelin reduced both visceral and liver fat after 6 months, and reducing liver fat is important because it helps fix insulin resistance and improves how the body handles glucose.

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

In a 12-month randomized, double-blind, placebo-controlled trial, continued tesamorelin treatment led to an 18% reduction in visceral adipose tissue, while discontinuation resulted in rapid fat regain, demonstrating a direct and reversible cause-and-effect relationship.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.